Clinical Trial Update: Lanreotide in the Treatment of Small Bowel Motility Disorders [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lanreotide for small bowel motility disorders has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Motility Disorder
• Intestinal Disease

Drugs mentioned

• Lanreotide (lanreotide)

Snippet

Sponsor: Northwell Health | Conditions: Gastrointestinal Motility Disorder, Intestinal Disease | Phase 2 | Status: COMPLETED | Results posted: 2021-01-15